These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 12120908

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.
    Ann Intern Med; 1998 Jul 01; 129(1):1-8. PubMed ID: 9652994
    [Abstract] [Full Text] [Related]

  • 3. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep 01; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD, Kipshoven C, Cöster A, Umbach R.
    Osteoporos Int; 1999 Sep 01; 9(2):171-8. PubMed ID: 10367046
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
    Guaydier-Souquières G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G.
    Osteoporos Int; 1996 Sep 01; 6(2):171-7. PubMed ID: 8704358
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
    Ringe JD, Dorst A, Faber H, Kipshoven C, Rovati LC, Setnikar I.
    Rheumatol Int; 2005 May 01; 25(4):296-300. PubMed ID: 15770482
    [Abstract] [Full Text] [Related]

  • 9. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X.
    Osteoporos Int; 1998 May 01; 8(1):4-12. PubMed ID: 9692071
    [Abstract] [Full Text] [Related]

  • 10. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
    Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ.
    J Bone Miner Res; 1990 Mar 01; 5 Suppl 1():S143-7. PubMed ID: 2339624
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
    Gutteridge DH, Holzherr ML, Retallack RW, Price RI, Will RK, Dhaliwal SS, Faulkner DL, Stewart GO, Stuckey BG, Prince RL, Criddle RA, Drury PJ, Tran L, Bhagat CI, Kent GN, Jamrozik K.
    Calcif Tissue Int; 2003 Jul 01; 73(1):33-43. PubMed ID: 14506952
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS, Stuckey BG, Drury P, Jones CE, Faulkner DL, Kent GN, Bhagat CI, Nicholson GC, Jamrozik K.
    Osteoporos Int; 2002 Jul 01; 13(2):158-70. PubMed ID: 11908491
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate.
    Meys E, Terreaux-Duvert F, Beaume-Six T, Dureau G, Meunier PJ.
    Osteoporos Int; 1993 Dec 01; 3(6):322-9. PubMed ID: 8292843
    [Abstract] [Full Text] [Related]

  • 18. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD, Farahmand P, Schacht E, Rozehnal A.
    Rheumatol Int; 2007 Mar 01; 27(5):425-34. PubMed ID: 17216477
    [Abstract] [Full Text] [Related]

  • 19. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug 01; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 20. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
    Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J.
    Calcif Tissue Int; 2008 Aug 01; 83(2):85-92. PubMed ID: 18626566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.